In an interview with the New York Times, Rebecca Boxer, MD, discusses how a new clinical trial will serve a population greatly in need of targeted COVID-19 treatments.
Collaboration between Kaiser Permanente’s care delivery system and research programs has driven the successful implementation of remdesivir clinical trials across regions.
Kaiser Permanente’s clinical trials help advance treatment for health conditions and diseases ranging from heart disease and cancer to AIDS and COVID-19.
In an effort to improve understanding and clinical practice guidelines around the novel coronavirus, Kaiser Permanente’s various research centers are quickly moving to investigate potential treatment for COVID-19.